来迪派韦/索磷布韦治疗台湾慢性丙型肝炎合并乙型肝炎感染患者:治疗后108周随访
在台湾111例HCV基因1或2型合并HBV感染患者中,接受来迪派韦/索磷布韦(90mg/400mg)每日一次治疗12周,所有患者(100%,111/111)在治疗后108周维持HCV抑制;HBV病毒学再激活发生于73%(81/111),临床再激活发生于9%(10/111),8例(7%,8/111)启动HBV治疗;基线HBV DNA和HBsAg水平与病毒学再激活相关。
要点
- 来迪派韦/索磷布韦治疗12周后108周,所有患者维持HCV抑制。
- HBV病毒学再激活发生于73%(81/111),多数(86%,70/81)在随访第12周前。
- HBV临床再激活发生于9%(10/111),可能延迟至治疗结束后3个月以上。
核心结论
- 在HCV/HBV合并感染患者接受直接抗病毒药物治疗HCV期间及随访中,HBV病毒学再激活发生于多数患者;大多数患者无症状,仅小部分启动HBV治疗;临床再激活可能在治疗结束后3个月以上仍发生。
研究设计与样本
- 在台湾,111例HCV基因1或2型合并HBV感染患者接受来迪派韦/索磷布韦(90mg/400mg)每日一次治疗12周,随访至治疗后108周。
主要发现
- 所有患者(100%,111/111)在治疗后108周维持HCV抑制。
- HBV病毒学再激活发生于73%(81/111);临床再激活发生于9%(10/111)。
- 多数HBV病毒学再激活(86%,70/81)发生于随访第12周前,而临床再激活通常更延迟。
- 8例(7%,8/111)启动HBV治疗。
- 回归分析中,基线HBV DNA和HBsAg水平与HBV病毒学再激活相关;基线ALT、HBV DNA和HBsAg水平与HBV临床再激活相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For patients coinfected with hepatitis C virus (HCV) and hepatitis B virus (HBV), HCV treatment with direct-acting antivirals can lead to HBV reactivation. We evaluated HBV reactivation during ledipasvir/sofosbuvir treatment and 108-week follow-up. METHODS: In Taiwan, 111 patients with HCV genotype 1 or 2 and HBV received ledipasvir/sofosbuvir (90mg/400mg) once daily for 12 weeks. HBV virologic reactivation was defined as postbaseline increase in HBV DNA from either less than the lower limit of quantification (LLOQ, 20 IU/mL) to equal to or more than LLOQ or equal to or more than LLOQ to >1 log10 IU/mL. HBV clinical reactivation was HBV virologic reactivation with alanine aminotransferase (ALT) >2× upper limit of normal. Factors associated with development of HBV virologic or clinical reactivation were evaluated with logistic regression analysis. RESULTS: All patients (100%, 111/111) maintained HCV suppression through 108 weeks after treatment. HBV virologic reactivation occurred in 73% of patients (81/111). Clinical reactivation occurred in 9% (10/111). The majority of HBV virologic reactivations (86%, 70/81) occurred by follow-up week 12, whereas clinical reactivation was generally more delayed. Eight (7%, 8/111) initiated HBV therapy. In regression analyses, baseline HBV DNA and hepatitis B surface antigen (HBsAg) levels were associated with HBV virologic reactivation and baseline ALT and HBV DNA, and HBsAg levels were associated with HBV clinical reactivation. CONCLUSION: Among HCV/HBV coinfected patients treated with direct-acting antivirals for HCV, HBV virologic reactivation occurred in a majority of patients during treatment and follow-up. In most patients, HBV virologic reactivation was asymptomatic; only a small proportion initiated HBV treatment. Notably, clinical reactivation may still occur >3 months after end of therapy. CLINICAL TRIALS REGISTRATION: NCT02613871.
引用
- Liu CJ, Sheen IS, Chen CY, et al. Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment. Clin Infect Dis. 2022. PMID: 34864948. doi:10.1093/cid/ciab971
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。